GAMBARAN PENGGUNAAN ANTIVIRUS PADA PASIEN RAWAT INAP NON-ICU COVID-19 DI RSUD ULIN BANJARMASIN
Abstract
COVID-19 menunjukkan penyebaran secara cepat dengan kondisi rawat inap yang beragam. Terapi antivirus menjadi salah satu terapi utama COVID-19. Sampai sekarang pengobatan antivirus untuk COVID-19 masih menggunakan obat yang telah ada sebelumnya dengan persetujuaan dalam keadaan mendesak. Tujuan umum penelitian ini adalah untuk mengetahui gambaran penggunaan antivirus pada pasien COVID-19 di ruang rawat inap non-ICU di RSUD Ulin Banjarmasin. Penelitian ini adalah penelitian deskriptif observasional yang menggunakan subjek pasien rawat inap non-ICU COVID-19 berusia >18 tahun berdasarkan catatan pusat data elektronik dan rekam medis yang lengkap pada periode 2020 - 2021. Pada penelitian ini didapatkan 146 subyek dengan antivirus yang digunakan antara lain lopinavir/ritonavir (32,7%), favipiravir (30,8%), remdesivir (19,9%) dan oseltamivir (16,7%). Berdasarkan rentang usia pasien non-ICU COVID-19 paling banyak pada usia 46-65 tahun (47,4%) dengan penggunakan antivirus favipiravir (32,4%) dan lopinavir/ritonavir (32,4%). Berdasarkan jenis kelamin, penggunaan antivirus terbanyak pada lopinavir/ritonavir (36,5%) pada laki-laki serta favipiravir (35,2%) pada perempuan. Berdasarkan komorbid yang paling banyak dimiliki penderita COVID-19 di ruang non-ICU adalah hipertensi (38,64%), dengan penggunaan antivirus remdesivir (26,47%). Berdasarkan durasi rawat inap tersingkat dengan luaran klinis sembuh, penggunaan antivirus terbanyak adalah favipiravir (28,08%) dengan rata-rata 13 hari rawat inap.
Keywords
Full Text:
PDFReferences
Instiaty, Sri Darmayani IGAAP, Marzuki JE, Angelia F, William, Siane A, et al. Antiviral treatment of COVID-19: a clinical pharmacology narrative review. Med J Indones. 2020;29(3):332–45.
Dhar Chowdhury S, Oommen AM, Chowdhury D. Epidemiology of COVID-19. J Dig Endosc. 2020;11(1):3–7.
World Health Organization. WHO coronavirus (COVID-19) dashboard with vaccination data [Internet]. 2021 [cited 2022 May 21]. Available from: https://covid19.who.int/
Kemenkes RI. Peta sebaran COVID-19 [Internet]. 2021 [cited 2022 May 21]. Available from: https://covid19.go.id/peta-sebaran
Ramatillah DL, Isnaini S. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. PLoS One. 2021;16(4):1–11.
Burhan E, Dwi Susanto A, Isbaniah F, Aman Nasution S, Ginanjar E, Wicaksono Pitoyo C, et al. Pedoman tatalaksana COVID-19. 4th ed. Kemenkes RI. PDPI, PERKI, PAPDI, PERDATIN, IDAI; 2022.
Kusumawardani LA, Maria N, Fanani YN. Potential drug interactions analysis of COVID-19 patients at a hospital in West Java. J Ilm Farm. 2021;17(2):181–96.
Nemer DM, Wilner BR, Burkle A, Aguilera J, Adewumi J, Gillombardo C, et al. Clinical characteristics and outcomes of non-ICU hospitalization for COVID-19 in a nonepicenter, centrally monitored healthcare system. J Hosp Med. 2021;16(1):7.
Meiliana ML, Hasmono D. Studi literatur: agen antivirus pada Pasien COVID-19 dengan penyakit ginjal kronis. J Farm Sains dan Terap. 2021;8(2):91–100.
Mahendro DS. Penggunaan antivirus untuk COVID-19. CDK. 2021;48(7):419–22.
Iwanami S, Ejima K, Su Kim K, Noshita K, Fujita Y, Miyazaki T, et al. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: a modeling study. PLoS Med. 2021;18(7):2–20.
Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A. Pedoman tatalaksana COVID-19. 3rd ed. Kemenkes RI. PDPI, PERKI, PAPDI, PERDATIN, IDAI; 2020.
Burhan E, Dwi Susanto A, Nasution SA, Ginanjar E, Wicaksono Pitoyo C, Susilo A, et al. Protokol tatalaksana COVID-19. 1st ed. Kemenkes RI. PDPI, PERKI, PAPDI, PERDATIN, IDAI; 2020. 1–50 p.
Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A. Pedoman tatalaksana COVID-19. 2nd ed. 2020. 1–112 p.
Rauf A, Abu-izneid T, Olatunde A, Khalil AA, Alhumaydhi FA, Tufail T, et al. COVID-19 Pandemic : Epidemiology, etiology, conventional and non-conventional therapies. 2020;17:1–32.
Deng J, Zhou F, Hou W, Heybati K, Ali S, Chang O, et al. Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: A meta-analysis. Future Virol. 2022;17(3):169–89.
Hossain MJ, Jannat T, Brishty SR, Roy U, Mitra S, Rafi MO, et al. Clinical efficacy and safety of antiviral drugs in the extended use against COVID-19: what we know so far. Biologics. 2021;1(2):252–84.
Dyer O. Covid-19: Indonesia becomes Asia’s new pandemic epicentre as delta variant spreads. BMJ. 2021;374(July):n1815.
Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501–8.
Damayanti H, Sajinadiyasa IGK, Risni HW, Sauriasari R. The effectiveness and safety of favipiravir in COVID-19 hospitalized patients at tertiary referral hospital Bali, Indonesia. Kesmas. 2021;16(4):289–97.
Ambrosino I, Barbagelata E, Corbi G, Ciarambino T, Politi C, Moretti AM. Gender differences in treatment of coronavirus disease-2019. Monaldi Arch Chest Dis. 2020;90(4):646–56.
Hidayani WR. Faktor faktor risiko yang berhubungan dengan COVID- 19 : literature review. J Untuk Masy Sehat. 2020;4(2):120–34.
Qureshi QH, Ashraf T, Rehman K, Khosa MK, Akash MSH. Therapeutic interventions of remdesivir in diabetic and nondiabetic COVID-19 patients: A prospective observational study conducted on Pakistani population. J Med Virol. 2021;93(12):6732–6.
Pettit NN, Pisano J, Nguyen CT, Lew AK, Hazra A, Sherer R, et al. Clinical infectious diseases remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk? Clin Infect Dis. 2021;73(11):3990–5.
Çinarka H, Günlüoğlu G, Çörtük M, Yurt S, Kiyik M, Koşar F, et al. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment. Turkish J Med Sci. 2021;51(4):1624–30.
DOI: https://doi.org/10.20527/ht.v6i2.9982
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Homeostasis
Homeostasis is licensed under a Creative Commons Attribution 4.0 International License
Program Studi Kedokteran Program Sarjana
Fakultas Kedokteran Universitas Lambung Mangkurat
Jalan Veteran No.128 Banjarmasin
Phone: +62-878-1546-0096
email : [email protected]